Novostia is a privately held medical device company developing an innovative artificial heart valve, designed for patients of any age, including children.

Novostia aims to provide young patients suffering from heart disease with a solution for life: the TRIFLO valve. In contrast to current valves, Novostia technology is lifelong durable and does not induce the formation of life-threatening blood clots, therefore do not require patients to take lifelong anticoagulant medication. TRIFLO will improve quality of life for millions of patients, while also significantly reducing overall healthcare costs.